Ligand Pharmaceuticals Inc. completed a $460 million private offering of 0.75% convertible senior notes due on October 1, 2030, with an initial conversion price set at approximately $194.79 per share. The offering, which closed on August 14, 2025, aims to reduce potential stock dilution and involved repurchasing 102,034 shares of common stock at $147.01 each.